Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Haematology"
DOI: 10.1111/ejh.13366
Abstract: Cytomegalovirus (CMV) is an opportunistic herpesvirus, and reactivation of infection is possible in immunocompromised patients. Historically, the risk for haematology patients is restricted to those treated with an allogeneic transplant or T‐cell depleting agents. Bortezomib… read more here.
Keywords: myeloma light; chain amyloidosis; bortezomib treatment; reactivation ... See more keywords
Overexpression of NIMA related kinase 2 in multiple myeloma and its relevance with disease features and prognosis to bortezomib treatment
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13723
Abstract: NIMA related kinase 2 (NEK2) promotes the malignant transformation and enhances the chemoresistance to proteasome inhibitor in multiple myeloma (MM) cell lines. The current study aimed to further investigate its correlation with clinical features and… read more here.
Keywords: nima related; related kinase; multiple myeloma; bortezomib treatment ... See more keywords
Azidohomoalanine (AHA) Metabolic Labeling Reveals Unique Proteomic Insights into Protein Synthesis and Degradation in Response to Bortezomib Treatment
Sign Up to like & getrecommendations! Published in 2025 at "Proteomes"
DOI: 10.3390/proteomes13040063
Abstract: Background: Multiple myeloma (MM) is essentially an incurable cancer, but treatments with proteasome inhibitors are widely used clinically to extend patient survival. While the mechanisms of proteasome inhibition by Bortezomib are well known, the cellular… read more here.
Keywords: bortezomib; treatment; degradation; bortezomib treatment ... See more keywords